A patient has subclinical folate deficiency. All of the following drugs can precipitate Megaloblastic anemia in this except
**Core Concept**
Folate deficiency can lead to megaloblastic anemia due to impaired DNA synthesis, causing abnormal red blood cell production. Subclinical folate deficiency may not cause noticeable symptoms but can still be a concern, especially when interacting with medications that interfere with folate metabolism.
**Why the Correct Answer is Right**
Megaloblastic anemia is often associated with folate or vitamin B12 deficiency. However, certain drugs can precipitate this condition by interfering with folate metabolism, such as inhibiting dihydrofolate reductase (DHFR), an enzyme crucial for folate conversion to its active form. Drugs like trimethoprim and pyrimethamine are known to inhibit DHFR, exacerbating folate deficiency and potentially leading to megaloblastic anemia.
**Why Each Wrong Option is Incorrect**
**Option A:** Metformin, a medication used to treat type 2 diabetes, does not directly interfere with folate metabolism or DHFR. It is therefore not expected to precipitate megaloblastic anemia in patients with subclinical folate deficiency.
**Option B:** Trimethoprim, an antibiotic, inhibits DHFR and can exacerbate folate deficiency, leading to megaloblastic anemia.
**Option C:** Pyrimethamine, an antimalarial drug, also inhibits DHFR and can precipitate megaloblastic anemia in folate-deficient patients.
**Option D:** Sulfasalazine, a medication used to treat inflammatory bowel disease, interferes with folate absorption and can contribute to folate deficiency, increasing the risk of megaloblastic anemia.
**Clinical Pearl / High-Yield Fact**
When managing patients with subclinical folate deficiency, it's essential to consider potential interactions with medications that can exacerbate folate deficiency, such as trimethoprim, pyrimethamine, and sulfasalazine.
**Correct Answer: A. Metformin**